SAN FRANCISCO, Jan. 9 /CNW/ -- Burrill Merchant Banking acted as
exclusive financial advisor to Faes Farma (Spain) on its recently-completed
commercial partnering of bilastine with the Menarini Group (Italy). Under the
terms of the agreement, Faes has licensed bilastine rights in Europe and other
regions to Menarini for the treatment of seasonal allergic rhinitis.
Bilastine is a new highly selective H1 antihistamine for once daily oral
administration. Allergic rhinitis prevalence in Europe is approximately 23%
and many patients are under-diagnosed and under-treated. Bilastine has been
assessed in multiple human trials involving 4,000 patients, including two
pivotal Phase III trials.
The agreement includes milestone payments and royalties of 10-15% of
annual sales in the licensed territories, incorporating the 27 EU member
states and 24 additional countries in Eastern Europe, Scandinavia, Central
Asia and the Mediterranean region. The Menarini Group is a privately held
company headquartered in Florence Italy with 12,000 employees and estimated
2007 turnover of euro 2,500M.
About Burrill Merchant Banking
Burrill Merchant Banking assists life science companies to identify,
negotiate and close strategic transactions. Service lines include:
-- Mergers & Acquisitions
-- Strategic Partnering from preclinical research to product development
-- Spin-Outs and Divestitures
-- Financing (Private Placements)
-- Advisory Services to define the role of transactions in achieving
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader
in life sciences with activities in Private Equity, Venture Capital, Merchant
Banking and Media. The Burrill family of venture capital funds has over $950
million under management and its merchant banking business is one of the
industry leaders in life sciences transactions. The company's 60 person
scientific and business team, supported by its 40-person Advisory Boards, the
strategic and financial network of its limited partners, and the close
relationships developed with numerous life sciences companies and management,
provide Burrill with unparalleled access and insight.
Burrill is the creator, sponsor and facilitator of over a dozen leading
industry conferences worldwide and publishes a wide range of bio-intelligence
reports including: The Personalized Medicine Report, The Stem Cell Report, and
periodic newsletters covering Canada, China, Europe, India, Japan and
Partnering/M&A. In association with the California Healthcare Institute,
Burrill publishes The Journal of Life Sciences -- a bimonthly magazine.
Burrill's flagship publication is its annual "State of the Industry" report,
the most recent 21st Edition being Biotech 2007: Life Sciences - A Global
Transformation. The 22nd Edition is entitled Biotech 2008: Life Sciences - A
20/20 Vision to 2020, available 1Q '08. These publications provide the latest
insight, intelligence and information on the life sciences industry.
For further information:
For further information: James Watson, Managing Director, Head of
Burrill Merchant Banking, +1-415-591-5430, email@example.com Web Site: